Petros Pharmaceuticals Appoints Experienced CFO as New Principal Financial Officer
PTPI has more than doubled off its 52-week low of $0.002 on light trading volume (0.2× avg).
Summary
Petros Pharmaceuticals announced a change in its top financial leadership, with the mutual departure of Mitchell Arnold and the immediate appointment of Robert Weinstein as the new Principal Financial Officer and Chief Accounting Officer.
Key Events · Executive and Board Changes · PTPI
-
Mutual Separation of Key Financial Officer
Mitchell Arnold, who served as Vice President of Finance, Principal Accounting Officer, and Principal Financial Officer, mutually separated from the company, effective June 18, 2026.
-
Severance Package Details
Mr. Arnold will receive a severance payment of $38,500, payment for 12.5 accrued unused PTO days totaling $11,105.77, acceleration of 3,000 unvested restricted shares, a $100 tax payment, and up to two months of COBRA premium coverage.
-
Appointment of Experienced Successor
Robert Weinstein was immediately appointed as Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer. Mr. Weinstein brings over 30 years of accounting and finance experience, including prior CFO roles at publicly-traded biotechnology companies.
Analysis · PTPI · Life Sciences
Petros Pharmaceuticals, a company facing significant financial challenges and going concern doubts, has replaced its Vice President of Finance, Principal Accounting Officer, and Principal Financial Officer. While the mutual departure of a key financial executive can introduce some disruption, the immediate appointment of Robert Weinstein, an experienced CFO with a background in publicly-traded biotechnology companies, is a positive development. His expertise could be crucial in navigating the company's liquidity issues and improving its financial stability.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTPI was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $256.1K. The 52-week trading range was $0.00 to $0.04. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.